Spironolactone Tablet, Film Coated
Product Images NDC 68071-4374

4 FDA label images from Nucare Pharmaceuticals,inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 68071-4374). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

68071 4374 3

68071 4374 3
Label for Spironolactone 50 mg film-coated tablets, packaged as 30 tablets. The label states the tablets are oval, light orange to orange, with a scored inscription 'AE' on the unscored side. Manufactured by Maas Pharmaceuticals Limited, Ahmedabad, India, and packed by NuCare Pharmaceuticals, Inc. The label includes NDC 68071-4374, product number P1330030, and storage instructions to keep at controlled temperature 68-77°F. It is marked Rx only with a child safety warning.*
FDA Label Image

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)
A survival probability curve comparing spironolactone and placebo groups over time in months. The chart shows two lines representing the probability of survival for patients on spironolactone versus placebo with sample sizes indicated (spironolactone n=822, placebo n=841). The x-axis is labeled in months and the y-axis represents probability. A log-rank p-value of less than 0.001 is noted.*
FDA Label Image

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)
A forest plot displaying hazard ratios (HR) and 95% confidence intervals (CI) for various patient subgroups comparing spironolactone versus placebo. Subgroups are categorized by age, sex, race, left ventricular ejection fraction (LVEF), heart failure type, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium level, digoxin use, ACE inhibitor use, and beta blocker use. The plot visualizes the effect size with HR and CI, indicating whether spironolactone is favored or placebo is favored across these groups.*
FDA Label Image

Chemical Structure (Spironolactone Structure Image)

Chemical Structure (Spironolactone Structure Image)
Chemical structure of spironolactone, the active ingredient in Spironolactone 50 mg film-coated tablets by NuCare Pharmaceuticals, Inc. The structure shows the molecular arrangement with characteristic rings and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.